Background: A significant hematological toxicity (HT) was observed during the retreatment of HIV-HCV genotype 1 coinfected patients in the ANRS HC26 TelapreVIH study. Alterations in renal function have been described with telaprevir (TVR). We examined the relationship between ribavirin (RBV) trough concentration (C), estimated glomerular filtration rate (eGFR) and hemoglobin (Hb) level, before and after introduction of TVR in the TelapreVIH study. Methodology: 69 HIV-HCV genotype 1 coinfected patients received PegIFN α2a (180μg/week) + RBV (1000-1200mg/day) for 4 weeks, followed by TVR (750/1125mg tid without/with efavirenz) + PegIFN-RBV for 12 weeks and finally PegIFN-RBV for 32 to 56 weeks. RBV C was determined by HPLC at W4 and W8, before and after TVR introduction. eGFR was estimated by the MDRD equation. Hb level and eGFR were determined at baseline (BL) and monthly. Factors associated with HT (defined by RBV dose reduction, prescription of EPO or blood transfusion) were analyzed by uni- and multivariate analysis. All data are presented as median [IQR]. Results: 67/69 patients were analyzed (female 21%, severe fibrosis/cirrhosis 40%, inosine triphosphatase (ITPA) CC 81%). Hb level was 154 g/L [145-160] at BL and declined to 131 g/L [119-143] at W4 and 116 g/L [104-129] at W8 (p<0.0001). eGFR remained normal between BL (97.9 mL/mn [81.4-110]) and W4 (103.4 mL/mn [87.4-122.1]), then declined to 86.3 mL/mn [74.8-104.5] at W8 (p<0.0001). eGFR stabilized until W16 and increased back to BL level at W20 (98.4 mL/mn [84.1-112.2]). The proportion of patients with stage 1 / stage 2 chronic kidney disease increased from 36% / 0% at BL to 50% / 6% at W8 (p=0.001) and 40% / 15% at W16 (p=0.001), then decreased to 35% / 0% at W20. RBV C increased from 1.88 mg/L (1.48 - 2.29) at W4 to 2.88 mg/L (2.16 - 3.71) at W8 (p<0.0001). RBV C was ≥3 mg/L in 12% of patients at W4 and in 45% at W8 (p<0.0001). Female gender was marginally associated with RBV C ≥3 mg/L at W4 (p=0.05). Female gender (p=0.02) and W8 eGFR (p=0.0001) were significantly associated with RBV C ≥3 mg/L at W8. HT was observed in 23.9% of patients at W4, 45.3% at W8 and 70% at W48. Female gender, BL Hb, BL eGFR, W8 eGFR and RBV C ≥3 mg/L at W8 were associated with W8 HT in the univariate analysis while body weight, CDC stage, CD4 cells count, type of antiretrovirals, liver fibrosis, HCV sub-genotype, ITPA genotype and SVR24 were not. In multivariate analysis, RBV C ≥3 mg/L at W8 (OR 7.7 [2.2-27.4]) and BL Hb <150 g/L (OR 6.4 [1.7-23.8]) were independently associated with W8 HT while gender, type of antiretrovirals, BL eGFR and W8 eGFR were not. Conclusions: Association of TVR to PegIFN+RBV was associated with a decrease in eGFR and a significant increase in RBV C, leading to RBV overexposure in 45% of the patients.